By: Azia Tariq, Section Editor – Myocardial infarctions, more commonly known as heart attacks, are prevalent in the United States. Each year, approximately 720,000 Americans suffer a heart attack.1 The approval of vorapaxar by the Food and Drug Administration (FDA) presents an additional treatment option for patients at high risk for myocardial infarction and stroke.1,2…

By: Svetlana Akbasheva, Staff Editor – For years, the medications that have been the mainstay of therapy for chronic heart failure have been angiotensin converting enzyme (ACE) inhibitors (or angiotensin receptor blockers), beta-blockers, loop diuretics, and aldosterone antagonists, with the occasional addition of digoxin or the hydralazine/isosorbide dinitrate combination.1 Now, a novel medicine is trying…

By: Sang Hyo Kim, Staff Editor – On March 19, 2014, the U.S Food and Drug Administration (FDA) approved miltefosine (Impavido®) for the treatment of leishmaniasis. Leishmaniasis is a disease caused by leishmania, a parasite that is transmitted to humans through sand fly bites. Although the majority of people affected with leishmaniasis are from tropical…

By: Nehali Parikh, PharmD Candidate c/o 2016 – Multiple sclerosis (MS) is an autoimmune disease that results in interrupted neurotransmission throughout the body. It occurs when the immune system mistakenly attacks myelin, the insulating layer surrounding nerve cells, causing the formation of scar tissue, called sclerosis. Fatigue, numbness, tingling, difficulty in walking, and dizziness are…